From a single spot purchase to a full delivery chain
All three partnership models share the same capability backbone: a governed supply network down to the base. The only difference is whether you already own the process. You can start with the smallest step — no need to bet on the entire chain up front.
Three partnership tiers, deepening step by step
Trust is staged: validate delivery discipline with the smallest order first, then move on to program development and tech transfer.
Best for: Have a defined CAS / spec / quantity
- Qualified-supplier screening & commercial terms
- Quality agreements & dossier documents
- Export, customs clearance & temperature-controlled delivery
- Dual-use items / ECCN pre-screening
Best for: Have a target molecule but lack a stable process or compliant capacity
- Route design & impurity attribution
- Pilot scale-up & process validation
- Analytical method development & transfer
- DMF / CEP document preparation
Best for: Need to land the process in your own capacity or a new region
- Full process package & analytical package transfer
- On-site scale-up support & validation batches
- Marketing authorization holder & license arrangements
- Long-term technical maintenance & iteration
Three capability layers form a non-replicable delivery discipline
Intelligence decides what to do, the supply network decides whether it can be done, and quality governance decides whether it can be done stably over the long term.
Working backward from blockbuster drugs and patent-expiry windows to the demand for key intermediates — we first say what to build, then talk supply. Every candidate runs a four-dimension screen (qualification × capacity × market × compliance) before entering the catalog.
Not a matchmaking directory, but a governed capacity network: specialty plants in chiral, fluorination, multi-step coupling, continuous-flow, etc. are classified and on record, each with an audit history, historical batches and a backup plan.
Quality agreements, change control, deviations & CAPA, full-batch COA traceability, plus PCF carbon-footprint data — this is where the coordinator's true technical assets lie.
Five coordination functions, one responsible entity
All five coordination functions are held by a single entity that plans and is accountable for the outcome — instead of you having to stitch five suppliers together.
Supplier screening & commercial terms: screened by qualification, capacity, export history and compliance record; commercial conditions folded into the master contract.
On-site audit & CAPA closure: audit findings and corrective actions are closed within the project — problems are not thrown back to the buyer.
Export, customs clearance & delivery: including dual-use items / ECCN pre-screening, cold chain and temperature-control documentation.
Route, impurity & scale-up: synthetic route evaluation, impurity attribution, scale-up and process validation.
DMF, CEP & filing documents: prepare CTD modules by target country and maintain across the lifecycle.
Unibest — one contract, one plan, one escalation window.
Chemistry capability on call
Process capabilities callable by route choiceThe following are stable capacities owned by group entities or already brought under governance agreements, matched to molecular difficulty — not sourced ad hoc from whoever is cheapest.
Asymmetric synthesis, enzymatic and crystallographic resolution are evaluated in parallel, compressing step count while preserving enantiomeric purity — suited to single-isomer intermediates.
Fluorination, trifluoromethylation and fluorinated building-block construction, covering both selective fluorination and late-stage introduction strategies.
Scale-up condition development for Suzuki, Buchwald–Hartwig, Negishi and other couplings, including catalyst selection and metal-residue control.
Multi-route comparison for heterocyclic systems such as pyridine, pyrimidine, indole and triazole, used for patent avoidance and cost optimization.
Built on Zhejiang Tize Pharmaceuticals' continuous-flow technology platform, rapid condition screening is converted into directly scalable continuous processes, improving safety and yield stability.
AI drug-design and process-prediction capabilities on the same platform, used for candidate-route ranking, impurity-risk prediction and scale-up condition recommendations.
Built on Guangzhou Taqing Environmental's Low-Temperature Supercritical (LTS) green technology, reducing waste and energy use while improving separation and purification efficiency.
Built on Shanghai Daoyi Zhenhe Biotechnology's lipid nanoparticle delivery capability, covering lipid formulation, encapsulation and lyophilization process development.
Continuous-flow process platform
Intrinsically safer continuous process developmentMoving batch parameters onto continuous equipment unchanged is the most common way this route fails. The capabilities below are supported by Zhejiang Tize Pharmaceuticals; each is assessed per molecule and route before scheduling.
The biggest obstacle in shifting from batch vessels to continuous flow is thatbatch process parameters do not transfer to continuous processes. Hand the design to a team that builds equipment but knows neither organic chemistry nor reaction engineering, and production stays inefficient indefinitely.
Kinetic models plus AI surrogate models are used to design and optimize the reaction parameters of each continuous process, rather than moving batch parameters straight onto continuous equipment.
Four core technologies
A closed loop from safety boundary to parameter control to intelligent optimizationA very high surface-to-volume ratio and excellent heat removal keep in-line hazardous inventory and potential temperature rise low; the inherent flame resistance and explosion protection of piping turn formerly runaway-prone reactions into intrinsically safe processes.
Reaction-path analysis and AI fitting of experimental data build the kinetic model that governs selectivity; the influence of temperature and molar flow ratio on selectivity is simulated to derive high-selectivity parameters and tailor the process to specific continuous equipment.
For unclear mechanisms, multiphase catalysis and multi-objective multi-unit operations, AI surrogate statistical models led by Bayesian optimization complement the kinetic model — approaching the global optimum without fitting the function as a whole and returning a Pareto front.
In-line techniques such as ReactIR and Spinsolve NMR, combined with artificial neural networks, estimate reaction-component concentrations in real time for multi-step monitoring and push process optimization toward full automation.
Batch vessel vs continuous flow: intrinsic safety
Redesigning the process boundary of hazardous reactions around intrinsic safety| Aspect | Batch vessel | Continuous flow |
|---|---|---|
| Reaction volume | Large volume required, poor cooling | High surface-to-volume ratio, excellent heat removal |
| Hazardous inventory | High reactant concentration, large in-line inventory | High at the inlet, decreasing along the path, small in-line inventory |
| Reaction control | Only through reactor temperature | Excellent heat removal plus heat-dilution effect |
| Cooling failure | Emergency handling required | Inherent flame resistance of piping, strong explosion protection |
Measured gains in continuous synthesis
Reaction types with continuous capability
Hazardous and strongly exothermic reactions suited to continuous conversionThe figures above are measured values from existing projects under specific molecules and process conditions; they are not a commitment for any particular project. Suitability for continuous operation and the achievable gain must be assessed case by case.
Project delivery chain
Route design → scale-up → commercial supply · handled by the group's own CDMO basesNo change of contact across the chain: process, quality, regulatory and supply are advanced through a single project window.
Around the target molecule and project stage, we provide route assessment, compound preparation and technical coordination — for compounds not in the catalog.
As the project evolves, we engage process R&D, analytical methods and scale-up production resources until commercial readiness.
Quality control, impurity profile and regulatory documentation are advanced together; modules required for DMF / CEP are prepared by target market.
Continuous supply is secured through batch scheduling and backup capacity, reducing the stock-out risk of a single site and a single batch.
Complete transfer of process, analytical methods and documents between pilot and commercial bases, shortening the scale-up cycle.
A single project window connects the demand side with the group's R&D, manufacturing and research resources, reducing multi-party coordination.
Group growth path
Four phasesFrom chemical trading in Ningbo in 2003 to a group network spanning R&D, CDMO, formulations, green technology and global market platforms.
Chemical trading built the first customer and supply-chain base; the group then moved into pharma intermediates and new-material R&D.
- 2003Ningbo Unibest · Global HQGroup headquartersChina · Ningbo
- 2007Shanghai Unibest BiopharmaPharma intermediates & new materials R&DChina · Shanghai
CDMO capacity for chemical drugs and APIs connected R&D output to production.
- 2008Xi'an CaijingCDMO for chemical drugs & intermediatesChina · Xi'an
- 2010Jiangsu WeikaierCDMO for APIs & pharma intermediatesChina · Nanjing
Adding four capabilities: formulation MAH, green processes, industrial investment and AI-driven process development.
- 2018Shenzhen Aoqi BiopharmaFormulation MAHChina · Shenzhen
- 2018Guangzhou Taqing EnvironmentalLTS green environmental technologyChina · Guangzhou
- 2020Ningbo QiandexinlongIndustrial investment & holding platformChina · Ningbo
- 2022Zhejiang Tize PharmaceuticalsAI drug design · continuous flow · mechanochemistryChina · Hangzhou
Overseas business platforms established one after another, and entry into macromolecule LNP delivery systems.
- 2023Asia-Pacific business centerNew Zealand · Auckland
- 2024European market accessFrance · Paris
- 2024North American commercial resourcesUSA · New York
- 2025SingaPharma Pte. Ltd.Pharma import & regional licensingSingapore
- 2026Shanghai Daoyi Zhenhe BiotechnologyMacromolecule LNP delivery systemsChina · Shanghai
How the capabilities empower each other
The group is not a flat collection of companies but a top-down empowerment chain: capital and governance provide the foundation, technology and process deliver scalable solutions, manufacturing and compliance carry out scale-up and registration, global platforms land products and rights in specific markets — and market requirements flow back into R&D.
Industrial investment, holding and team incentives provide long-term capital and a governance framework for the operating entities.
Capital empowerment·A single investment platform invests externally while operating entities focus on their own business.
Pharma intermediates and new-material R&D, combined with AI drug design, continuous flow and mechanochemistry, delivers scalable routes and reaction conditions.
Process & route empowerment·Tize's technology platform recommends candidate routes and reaction conditions to the CDMOs, reducing scale-up risk.
CDMO for chemical drugs and intermediates, API CDMO, formulation MAH and macromolecule LNP delivery — carrying scale-up and registration files.
Product & rights empowerment·Products and registration files from the manufacturing layer are landed by the global platforms.
Regional entities handle import, licensing, registration and commercialisation, landing products and rights in specific markets.
Market & regulatory feedback·Registration and quality requirements of target markets define the next steps for R&D and processes.
Guangzhou Taqing Environmental (LTS low-temperature supercritical technology, 2018) provides green process and waste-reduction solutions to every manufacturing base. It reaches into both the technology and the manufacturing layer rather than forming a layer of its own.
Entities and years are compiled from public disclosures; entries within a phase are ordered by year of entry. Shareholding ratios and intra-group transaction arrangements are not public information.
Scope 3-Ready Supply
Low-Carbon Intermediates for EU and US buyersSpec-driven intermediates, held to the same qualification discipline as every Unibest project.
Product carbon-footprint data packaged to the buyer's Scope 3 disclosure requirements.
A continuous decarbonization roadmap maintained with the production site — not a one-off static figure.
Methodology notes and evidence chains aligned to common buyer questionnaires.